Trovafloxacin Mesylate
FDA-approved product (tablet, oral), marketed as Trovan.
- Registered studies
- 1
- Lab records
- 7
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Fluoroquinolones
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01MA13
Repurposing investigation
Trovafloxacin Mesylate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis76.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 0 of 1 lab record
- E. coli: measured active in 1 of 2 lab records
- K. pneumoniae: measured active in 4 of 4 lab records
Show the 7 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Trovafloxacin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Etrasimod ArginineExisting use: Ulcerative colitis64.1% AI-predicted activityagainst MRSANo documented evidence found
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more64.1% AI-predicted activityagainst MRSA50+ registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more63.6% AI-predicted activityagainst MRSA50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome63.6% AI-predicted activityagainst MRSA6 registered studies
- Nafarelin AcetateExisting use: Endometriosis63.6% AI-predicted activityagainst MRSA12 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents63.6% AI-predicted activityagainst MRSA1 registered study
- Vinorelbine TartrateExisting use: Cancer, Neoplasm63.6% AI-predicted activityagainst MRSA50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis63.5% AI-predicted activityagainst MRSANo documented evidence found
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances63.4% AI-predicted activityagainst MRSA50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema63.4% AI-predicted activityagainst MRSA33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria63.3% AI-predicted activityagainst MRSA39 registered studies
- LypressinExisting use: Vasopressin and analogues63.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia
NCT00548002 · start 1999-01
Registered record
- Registry ID
- NCT00548002
- Conditions
- Staphylococcus Aureus; Bacteremia; Endocarditis; Sepsis
- Interventions
- trovafloxacin and levofloxacin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1999-01
- Completion
- 2002-08
- Enrolment
- 430
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStaphylococcus Aureus; Bacteremia; Endocarditis; SepsisInterventiontrovafloxacin and levofloxacinPhaseNot recordedRegistry statusCompleted